The dose tracker built for Semaglutide, Tirzepatide, and Retatrutide
Weekly dosing. Multi-week titration. Side-effect curves you can’t fake. Most habit trackers weren’t built for this. DoseCraft was.
Why GLP-1 needs its own tracker
Weekly dosing breaks habit-tracker math. Most apps assume daily cadence. GLP-1 protocols are weekly with multi-week titration steps. The compliance picture only works when the tracker thinks in weeks, not days.
Titration is the whole game. Most users fail at the dose-escalation step (week 4 → 8 → 12) because nausea spikes and they don’t know whether to push, pause, or pull back. Logged side-effect data against dose-step is the difference between “I quit” and “I held the dose for 2 extra weeks and crossed through.”
Plasma concentration matters. With a 5–7 day half-life, missing a dose by 24 hours barely matters. Missing by 3+ days drops you below therapeutic threshold and you start over. The half-life chart shows when you’re inside the window vs outside it.
The three compounds, compared
Same family, different receptor profiles. Pick by goal, evidence depth, and tolerability.
Semaglutide
GLP-1Single-receptor GLP-1 agonist. The most-prescribed, best-evidenced.
- Receptor
- GLP-1 only
- Half-life
- ~7 days
- Cadence
- Weekly subcutaneous
- Typical loss
- ~15% body weight @ 78 weeks (STEP-1 trial)
Tirzepatide
GLP-1Dual GLP-1 + GIP agonist. Stronger weight-loss data, comparable tolerability.
- Receptor
- GLP-1 + GIP (dual)
- Half-life
- ~5 days
- Cadence
- Weekly subcutaneous
- Typical loss
- ~21% body weight @ 78 weeks (SURMOUNT-5 head-to-head)
Retatrutide
GLP-1Triple GLP-1 + GIP + glucagon agonist. Phase III, not yet FDA-approved.
- Receptor
- GLP-1 + GIP + Glucagon (triple)
- Half-life
- ~6 days
- Cadence
- Weekly subcutaneous
- Typical loss
- ~24% body weight @ 48 weeks (Phase II data)
What you get
The features that actually move the needle when you’re titrating a GLP-1.
Titration scheduling
Most GLP-1 protocols ramp dose every 4 weeks (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg for Semaglutide). The app schedules each step automatically and reminds you the day-of.
Side-effect log
Nausea, GI distress, fatigue, injection-site reactions — log severity 1–5 against the dose schedule. Spot which step is intolerable before it derails the cycle.
Weight + body comp trend
Track weight, waist, body-fat % over time. Charts overlay against dose escalation so you see what's actually working vs noise.
Half-life-aware reminders
Half-life chart shows when last week's dose drops below therapeutic threshold. Set the next injection at the same plasma-concentration window every time.
Reconstitution math
5 mg vial + 2 mL bac water → 250 mcg per 0.05 mL → 5 units on a U-100. Calculator runs the math, syringe visual confirms the draw line.
Side-effect playbook
Coach has a playbook for the most common GLP-1 side effects — when to push through, when to drop a dose, when to hold. Cited research, not hot takes.
“Both Semaglutide and Tirzepatide are weekly subcutaneous incretin agonists, but they hit different receptors. The difference shows up in efficacy, side-effect profile, and price. If cost is a factor, Semaglutide is generally cheaper. If maximum efficacy with comparable tolerability is the goal, Tirzepatide is the better-evidenced choice. Both require slow titration over 16+ weeks to minimize GI effects.”
Read 5 more Coach examplesTrack your titration the right way
14-day free trial. Full Pro access. No credit card required. Cancel from settings.
Start free trialDoseCraft is an educational tracking platform. Semaglutide, Tirzepatide, and Retatrutide require a prescription in most jurisdictions. Always consult a licensed healthcare professional before starting, modifying, or stopping any medication. DoseCraft does not sell, distribute, or facilitate the purchase of any compound.
Trial data + Coach reasoning sourced from our curated knowledge graph — see methodology.